The
View from Here
Frank Sams-Dodd
Drug discovery – like science – moves in phases. The first phase was represented by the physiology-based approach where drugs are evaluated in organ systems or intact animals for their ability to induce certain physiological effects or to reverse symptoms in disease models...
Read
more...
Upcoming Issues
Issue 10
October '07
Upcoming Biotech Hotspots
Issue 11
November '07
Chemoinformatics
Issue 12
December '07
A Review of 2007
|
A
review of 2006
|
| |
Top
Reviews |
 |
Cell microarrays in drug discovery
Castel D, Pitaval A, Debily M-A, Gidrol X
Drug Discovery Today
There is an increasing need for systematic cell-based assays in a high-throughput screening (HTS)
format to analyze the phenotypic consequences of perturbing mammalian cells with drugs, genes,
interfering RNA...
|
| |
High-content screening moves to the front of the line
Haney SA, LaPan P, Pan J, Zhang J
Drug Discovery Today
High-content screening (HCS) has been used in late-stage drug discovery for a decade. In the past few
years, technological advances have expanded the role of HCS into the early stages of drug discovery,
including high-throughput screening and hit-to-lead studies...
|
| |
Research & market strategy: how choice of drug discovery approach can affect market position
Sams-Dodd F
Drug Discovery Today
In principal, drug discovery approaches can be grouped into target- and function-based, with the
respective aims of developing either a target-selective drug or a drug that produces a specific biological
effect irrespective of its mode of action...
|
|
| |
Abstracts
of Key Research Articles
Glia Proinflammatory Cytokine Upregulation as a Therapeutic Target for Neurodegenerative Diseases: Function-Based and Target-Based Discovery Approaches
Van Eldik LJ, Thompson WL, Ranaivo HR, Behanna HA, Martin Watterson D
Int Rev Neurobiol. 2007; 82: 277-296
Activity-dependent neuroprotective protein: From gene to drug candidate
Gozes I
Pharmacol Ther. 2007; 114(2): 146-154
Discovery and validation of drug targets for tumour angiogenesis
Kremmidiotis G, Lavranos TC
Expert Opin Ther Targets 2005; 9(2): 211-215
Can cell systems biology rescue drug discovery?
Butcher EC
Nat Rev Drug Discov. 2005; 4(6): 461-467
Multiplexed high content screening assays create a systems cell biology approach to drug discovery
Taylor DL, Giuliano KA
Drug Discovery Today: Technologies 2005; 2(2):149-154
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann GR, Lehár J, Keith CT
Drug Discov Today 2007; 12(1-2):34-42
Functional screening of traditional antidepressants with primary cortical neuronal networks grown on multielectrode neurochips
Gramowski A, Jügelt K, Stüwe S, Schulze R, McGregor GP, Wartenberg-Demand A, Loock J, Schröder O, Weiss DG
Eur J Neurosci. 2006; 24(2): 455-465
Systems cell biology knowledge created from high content screening
Giuliano KA, Cheung WS, Curran DP, Day BW, Kassick AJ, Lazo JS, Nelson SG, Shin Y, Taylor DL
Assay Drug Dev Technol. 2005; 3(5):501-514
Cellular imaging in drug discovery
Lang P, Yeow K, Nichols A, Scheer A
Nat Rev Drug Discov. 2006; 5(4):343-356
Plant natural products: Back to the future or into extinction?
McChesney JD, Venkataraman, SK, Henri JT
Phytochemistry 2007; 68(14):2015-2022 |
|
